Cuba announced this Thursday that will start clinical trials of two new vaccine projects against covid-19, with which there are already four possible drugs created on the island to combat the epidemic.
Created by the Center for Genetic Engineering and Biotechnology of Cuba (CIGB), vaccine candidates are named Mambisa (intranasal) and Abdala (intramuscular) and each will be tested in two phases, state television reported without offering further details or specifying the start date of the studies.
“Cuba already has four vaccine candidates in the clinical trial phase, a feat of the biotechnology and pharmaceutical industry “of the country, wrote on Twitter the state-run Business Group of the Biotechnology and Pharmaceutical Industries of Cuba (BioCubaFarma).
The trials of Soberana 01, the first Cuban vaccine project against the new coronavirus, began at the end of last August. The process is progressing without incident at the moment and has had the participation of more than 700 volunteers.
Unlike other more advanced international projects, created from adenoviral vectors or inactivated viruses, this Cuban drug is based on a protein recombinant.
Meanwhile, Sovereign 02 is a conjugate vaccine, in which the virus antigen and tetanus toxoid are combined, and it has been tested since last October 19.
Cuba, which accumulates 8,075 positives since the beginning of the coronavirus epidemic and 133 deaths, with a renowned biotechnology and pharmaceutical industry that currently produces eight disease vaccines such as meningitis, lung cancer (therapeutic) and solid tumors, among others.
The authorities have indicated that they hope to vaccinate against covid-19 to an “important part” of the Cuban population before the end of the first semester of 2021.
Since October most of the Caribbean country entered a stage of “new normal” that includes the operation of activities and services at full capacity, although some measures are maintained, such as the mandatory use of the mask outside the home and physical distancing.